UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2160-7
Program Prior Authorization/Medical Necessity
Medication Oxervate® (cenegermin-bkbj) ophthalmic solution
P&T Approval Date 2/2019, 2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Oxervate (cenegermin-bkbj) ophthalmic solution is a recombinant human nerve growth
factor indicated for the treatment of neurotrophic keratitis.
2. Coverage Criteriaa:
A. Neurotrophic Keratitis
1. Oxervate will be approved based on all the following criteria:
a. Diagnosis of Stage 2 or 3 neurotrophic keratitis
-AND-
b. History of failure to at least one OTC ocular artificial tear product (e.g., Systane®
Ultra, Akwa® Tears, Refresh Optive®, Soothe® XP)
-AND-
c. Prescribed by or in consultation with one of the following:
(a) Ophthalmologist
(b) Optometrist
Authorization will be issued for one 8 week authorization
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
© 2025 UnitedHealthcare Services Inc.
1
4. References:
1. Oxervate [prescribing information]. Boston, MA: Dompé U.S. Inc..; December 2024.
2. Sacchetti, M., Lambiase, A. Diagnosis and management of neurotrophic keratitis. Clinical
Ophthalmology 2014;8: 571-9.
Program Prior Authorization/ Medical Necessity - Oxervate (cenegermin-bkbj)
Change Control
2/2019 New program.
2/2020 Annual review. Updated references.
2/2021 Annual review with no changes to clinical coverage criteria.
2/2022 Annual review with no change to clinical criteria.
2/2023 Annual review with no change to clinical criteria.
2/2024 Annual review with no change to clinical criteria. Updated reference.
2/2025 Annual review with no change to clinical criteria. Updated reference.
© 2025 UnitedHealthcare Services Inc.
2